Latest Research And Development News

Acusensus Limited reported a robust 40% increase in revenue to $40.3 million for the half-year ended December 2025, driven by new contracts and international growth. However, the company recorded a substantial $20.8 million loss, largely due to a $16 million litigation settlement and strategic investments in future growth.

AI-Media Technologies has reported a robust first half of FY26, achieving an 80% increase in annual recurring revenue driven by its LEXI suite and unveiling a new Hardware as a Service model set to transform its business.

NeuroScientific Biopharmaceuticals reported a $1.7 million loss for the half-year ending December 2025, driven by ongoing R&D investments. The company progressed clinical treatments for Crohn’s disease and glaucoma, alongside key leadership appointments and strategic partnerships.

Cleo Diagnostics reported a 53% drop in revenues and a slight increase in net loss to $1.98 million for H1 2025, while progressing its pivotal FDA clinical trial for an ovarian cancer blood test with strong regulatory and commercial milestones.

Immuron Limited reported a narrower half-year loss alongside record sales growth and FDA approval for its IMM-529 drug candidate, signalling promising clinical and commercial momentum.

Global Health Limited reports a modest half-year loss reduction alongside a steady rise in recurring SaaS revenue, signaling progress in its digital healthcare transformation.

HITIQ Limited reported a $2.9 million loss for the half-year ending December 2025, while making significant strides in international market expansion and strategic partnerships. The company’s capital raising efforts aim to support its transition from technology validation to commercial execution.

Anatara Lifesciences reports a significantly reduced net loss for H1 FY2026, driven by promising pre-clinical results in its anti-obesity program and a successful $1.2 million capital raise. The company also highlights positive Phase II trial outcomes for its gastrointestinal health product GaRP.

Optiscan Imaging reports a sharp 43% drop in revenue and a 43% rise in losses for H1 FY26, driven by restricted research funding in key markets. The company bolsters its balance sheet with a $17.75 million capital raise to advance clinical studies and regulatory approvals.

Epiminder Limited has reported a $21.7 million loss for the half-year ending December 2025, alongside a successful $125 million IPO that fuels its commercialisation of the FDA-approved Minder epilepsy monitoring device.

VEEM Ltd posted a significant half-year loss of $19.5 million, driven by a 30% revenue decline and a $24.8 million impairment on gyro product development. Despite setbacks, new product launches and US defence market progress offer a hopeful outlook.

Imricor Medical Systems saw a sharp 69.5% decline in revenue for 2025, driven by clinical trial impacts, yet narrowed its net loss to $25.3 million as it secured FDA clearance for key products post-year-end.